To conclude, more mature safety data and a deeper analysis of the biologic mechanisms will be essential to understand if PD-1/PD-L1 inhibitors may be included in the armamentarium for the treatment of MM patients. This evidence concerns the gene PDCD1 and Miyoshi myopathy.